髓少突细胞糖蛋白抗体与双边和复发性视神经炎和多发性硬化症有不同的辐射资料或Aquaporin-4 Antibody-associated视神经炎(P3.001)

文摘

目的:我们进行第一集视神经炎的临床和放射学描述(上)患者髓少突细胞糖蛋白antibody-associated (MOG-ON), aquaporin-4 antibody-associated (AQP4-ON),和多发性硬化症(毫秒)。我们提出会有特定的放射性预测根据的原因。背景:早期识别的病因和预后影响治疗决策。设计/方法:我们进行了以流式细胞术测定使用HEK293细胞表达完整的人类生活MOG测试血清23成人AQP4 antibody-negative neuromyelitis视谱系障碍。蒙蔽neuroradiological评估随后进行磁共振成像的50个患者(平均年龄24岁,射程3-58,41岁女性)的第一集,包括MOG-ON (n = 19), AQP4-ON (n = 11),毫秒(n = 13)和非保密(n = 7)。结果:MOG抗体检测在9/23的病人,他们举行了双边。MOG-ON患者更有可能复发,是类固醇响应。两国参与在MOG-ON更为常见,AQP4-ON比毫秒(84 v (percnt)。82[percnt] v.23[percnt]), optic nerve head swelling was more common in MOG-ON (53[percnt] v.9[percnt] v.0[percnt]), chiasmal involvement was more common in AQP4-ON (5[percnt] v.64[percnt] v.15[percnt]), and bilateral optic tract involvement was more common in AQP4-ON (0[percnt] v.45[percnt] v.0[percnt]). Retrobulbar optic nerve involvement was more common in MOG-ON, whereas intracranial optic nerve involvement was more common in AQP4-ON. MOG-ON and AQP4-ON had longer lesion lengths and lesion extent scores than MS-ON. AQP4-ON more frequently had severe and sustained visual impairment. Conclusions: MOG antibodies are associated with a bilateral ON phenotype and are steroid responsive. MOG and AQP4-ON are frequently bilateral and longitudinally extensive, compared with MS-ON. MOG-ON tends to involve the anterior optic pathway whereas AQP4-ON tends to involve the posterior optic pathway. These radiological predictors may expedite diagnosis at the first presentation of ON, with therapeutic and prognostic implications.

披露:拉马纳坦博士已经收到了那个人赔偿NHMRC澳大利亚和基础。测前博士没有披露。Barnes博士没有披露。Tantsis博士没有披露。Reddel博士已经收到Genzyme赛诺菲的研究支持,生原体,CSL,巴克斯特。汉德森博士没有披露。Vucic博士获得了研究支持Idec,诺华公司,拜耳,CSL和Genzyme。戈尔曼博士没有披露。本森博士没有披露。高山博士没有披露。 Dr. Riney has received research support from Novartis. Dr. Barnett has received research support from Novartis Pharmaceuticals. Dr. Parratt has received research support from Multiple Sclerosis Research Australia, Genzyme, Novartis, Merck Serono and Bayer Schering, Biogen Idec and CSL. Dr. Hardy has nothing to disclose. Dr. Leventer has nothing to disclose. Dr. Merheb has nothing to disclose. Dr. Nosadini has nothing to disclose. Dr. Fung has nothing to disclose. Dr. Brilot-Turville has received research support from Star Scientic Foundation, Trish MS Research Foundation, MSRA, MS Angels Melbourne, NHMRC, and the Petre Foundation. Dr. Dale has received research support from Star Scientific Foundation, Trish MS Research Foundation, MSRA, NHMRC Australia, and the Petre Foundation.